GCI picks up work for new diabetes product

GCI’s healthcare arm has picked up the pounds 200,000 fee account for a new diabetes treatment from pharmaceutical firm Novo Nordisk, the world’s leading producer of insulin.

GCI’s healthcare arm has picked up the pounds 200,000 fee account

for a new diabetes treatment from pharmaceutical firm Novo Nordisk, the

world’s leading producer of insulin.



The new product, repaglinide, is a treatment for the management of

non-insulin dependent diabetes. GCI won the account following a two-way

competitive pitch against Shire Hall.



’We will conduct a pre-launch and launch programme for the next 18

months,’ said GCI healthcare director Catherine Warne.



The win also includes Novo Nordisk’s existing portfolio of insulin

products, which include injection and monitoring systems for diabetes

care. The products were previously handled for six years by Lowe Fusion

(formerly Fusion), which declined to repitch for the business.



Non-insulin dependent diabetes occurs when the pancreas becomes unable

to produce sufficient insulin to regulate blood glucose effectively. It

is considered to be the rising form of diabetes in developed countries,

where ageing populations and obesity contribute to an increasing

prevalence.



Novo Nordisk was formed by the merger in 1989 of Danish insulin

producers Novo and Nordisk. As well as diabetes treatments, the company

produces drugs for the treatment of depression and haemophilia.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.